Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades

[1]  H A Feldman,et al.  Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting. , 1972, Analytical biochemistry.

[2]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[3]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[4]  T. Heffner,et al.  The alpha 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920. , 1989, European journal of pharmacology.

[5]  R. Schreiber,et al.  Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. , 1994, European journal of pharmacology.

[6]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[7]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[8]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[9]  G. Aghajanian,et al.  Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release , 1999, Brain Research.

[10]  G. Aghajanian,et al.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  W. Spooren,et al.  Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. , 2000, European journal of pharmacology.

[12]  J. Gewirtz,et al.  Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors , 2000, Neuropsychopharmacology.

[13]  P. Ornstein,et al.  [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  J. Gewirtz,et al.  A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex , 2001, Neuroscience.

[15]  Marc Laruelle,et al.  The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development , 2002, European Neuropsychopharmacology.

[16]  Paul R Selvin,et al.  Principles and biophysical applications of lanthanide-based probes. , 2002, Annual review of biophysics and biomolecular structure.

[17]  S. Sealfon,et al.  Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.

[18]  S. Snyder,et al.  Schizophrenia: Neural Mechanisms for Novel Therapies , 2003, Molecular medicine.

[19]  H. Holcomb,et al.  Phenotype of schizophrenia: a review and formulation , 2005, Molecular Psychiatry.

[20]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[21]  Z. Xiang,et al.  A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis , 2007, Molecular Pharmacology.

[22]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[23]  J. Pin,et al.  Activation of a Dimeric Metabotropic Glutamate Receptor by Intersubunit Rearrangement* , 2007, Journal of Biological Chemistry.

[24]  C. Corti,et al.  The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity , 2008, Psychopharmacology.

[25]  Michel Bouvier,et al.  International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers , 2007, Pharmacological Reviews.

[26]  G. Marek,et al.  Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex , 2008, Neuroscience Letters.

[27]  N. Tinel,et al.  Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.

[28]  Franz X Vollenweider,et al.  Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.

[29]  Graeme Milligan,et al.  Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors* , 2008, Journal of Biological Chemistry.

[30]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[31]  D. Cussac,et al.  Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. , 2008, European journal of pharmacology.

[32]  Michel Bouvier,et al.  Building a new conceptual framework for receptor heteromers. , 2009, Nature chemical biology.

[33]  Eric Trinquet,et al.  Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration , 2009, The EMBO journal.

[34]  F. Nicoletti,et al.  Activation of mGlu2/3 Metabotropic Glutamate Receptors Negatively Regulates the Stimulation of Inositol Phospholipid Hydrolysis Mediated by 5-Hydroxytryptamine2A Serotonin Receptors in the Frontal Cortex of Living Mice , 2009, Molecular Pharmacology.

[35]  L. Bohn,et al.  Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo , 2010, The Journal of Neuroscience.

[36]  G. Marek,et al.  LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. , 2010, Current opinion in investigational drugs.

[37]  L. Prézeau,et al.  Functional crosstalk between GPCRs: with or without oligomerization. , 2010, Current opinion in pharmacology.

[38]  S. Sealfon,et al.  Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists , 2011, Neuroscience Letters.

[39]  S. Sealfon,et al.  Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors , 2011, Neuropharmacology.

[40]  Eric Trinquet,et al.  A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Davide Provasi,et al.  Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs , 2011, Cell.

[42]  osé Morenoa,et al.  etabotropic glutamate mGlu 2 receptor is necessary for the pharmacological nd behavioral effects induced by hallucinogenic 5-HT 2 A receptor agonists , 2011 .

[43]  B. Kinon,et al.  A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia , 2013, BMC Psychiatry.